Evotec SE header image

Evotec SE

EVT

Equity

ISIN DE0005664809 / Valor 505433

Xetra (2026-02-20)

EUR 6.10-0.13%

Evotec SE
UMushroom community rating:

4.29 7 votes No rating yet

NegativeNeutralPositive

About company

Evotec SE is a global drug discovery and development partnership company headquartered in Germany, specializing in providing integrated solutions to the pharmaceutical and biotechnology industries. The company leverages its extensive expertise in areas such as medicinal chemistry, biology, and data science to support the development of new therapeutics across various therapeutic areas, including neuroscience, oncology, and metabolic diseases. Evotec collaborates with a diverse range of partners, including major pharmaceutical companies, biotech firms, and academic institutions, to advance innovative drug candidates from early discovery through clinical development. In the first quarter of 2025, Evotec reported progress in strategic partnerships and the implementation of initiatives aimed at achieving sustainable and profitable growth, reinforcing its position as a key player in the biopharmaceutical landscape.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-28.6%1Y

-67.7%3Y

-82.3%5Y

Performance

59.3%1Y

66.6%3Y

58.8%5Y

Volatility

1278 M

Market cap (USD)

245,041

Daily traded volume (Shares)

8.73 / 8.45

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.29

7 votes

Performance:

4.29

Innovation:

4.29

Society:

4.00

Nature:

3.86

Meret Jaggi

Switzerland, 30 May 2022

Oliver Moon

Switzerland, 30 May 2022

German biotech/ pharma company. Decent upside potential. Analyst buy. Good performance history. Seems good to me.

Atanas WI Atanasov

United Kingdom, 30 May 2022

EQUITIES OF THE SAME SECTOR

Siemens Healthineers AG

Siemens Healthineers AG Valor: 40652181

Annual Return

-50%0%+50%

Risk level

110

2.17%EUR 42.35

Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA Valor: 332902

Annual Return

-50%0%+50%

Risk level

110

-0.04%EUR 52.06

Fresenius Medical Care AG

Fresenius Medical Care AG Valor: 520878

Annual Return

-50%0%+50%

Risk level

110

1.18%EUR 41.17

Evolent Health Inc

Evolent Health Inc Valor: 28153126

Annual Return

-50%0%+50%

Risk level

110

0.72%USD 2.79

Vita 34 AG

Vita 34 AG Valor: 2333201

Annual Return

-50%0%+50%

Risk level

110

0.95%EUR 5.30

Maternus-Kliniken AG

Maternus-Kliniken AG Valor: 335800

Annual Return

-50%0%+50%

Risk level

110

-2.02%EUR 0.97

QuidelOrtho Corporation

QuidelOrtho Corporation Valor: 119356965

Annual Return

-50%0%+50%

Risk level

110

-4.79%USD 22.48

iRhythm Technologies Inc

iRhythm Technologies Inc Valor: 34117792

Annual Return

-50%0%+50%

Risk level

110

-4.98%USD 150.96

Novartis Inc

Novartis Inc Valor: 1200526

Annual Return

-50%0%+50%

Risk level

110

-0.02%CHF 126.46

Savaria Corp

Savaria Corp Valor: 1385257

Annual Return

-50%0%+50%

Risk level

110

0.43%CAD 25.71

SIX

FactSet

Clearbit

Logos provided by Clearbit